Healthcare & Life Sciences
Therachon
Switzerland
acquiredacquired
acquired
Stage
1
Investors
About
Therachon was a biotechnology company focused on developing treatments for rare genetic diseases. Its primary program was TA-46, an investigational drug for achondroplasia.
Explore Therachon's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.